Considering that intramyocardialCE accumulation in the heart ispromoted by high-prevalence pathological situations, including ischemia,12−14 hypercholesterolemia,16−18 and obesity,26 all of them associated with dyslipemia, LRP1-based immunotherapyemerges as a valuable strategy for modulating not only cardiac sensitivitybut also cardiac fibrosis in these groups of patients. Here, LRP1 is linked to Hypercholesterolemia.